ClinicalTrials.gg
RecruitingNCT05211570Updated Oct 2, 2025

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1/2 interventional study of AB8939 and Venetoclax in Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse and Myelodysplastic Syndrome Acute Myeloid Leukemia, sponsored by AB Science. Recruiting at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by AB Science · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 200 studies in Leukemia, Myeloid, Acute with a site in Spain — 35 open to participants now, 61 under way, 22 of them phase 3. Leukemia, Myeloid, Acute · Spain.

Planned enrollment
116th of 189
78 · median 120
Started
2022
with 11 others
Phase 1/2
42 of 200
9 open now
Primary completion
2026-08
later than 13 of 60 live
Registered
161st of 200
by date

Among the 200 studies in Leukemia, Myeloid, Acute with a site in Spain, this one is the 116th largest by planned enrollment of the 189 interventional ones that give a count, is one of 12 that started in 2022, is one of 42 in phase 1/2, reaches primary completion later than 13 of the 60 other live ones, and was the 161st registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

35 of the 200 studies in Leukemia, Myeloid, Acute with a site in Spain are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 200 studies in Leukemia, Myeloid, Acute with a site in Spain, or all of them as a file.
02

Study summary

The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.

Read the detailed description

This is a Phase 1/2, open-label, multi-center, non-randomized, 2-part study in patients with refractory and relapsed AML and refractory myelodysplastic syndrome.

Study AB18001 has a multi-stage design. The first part is a dose escalation study that aims to determine the safety, tolerability and pharmacokinetic profiles of consecutive daily intravenous administration of AB8939 in patients with refractory or relapsed AML or patients with refractory myelodysplastic syndrome, and to determine the recommended dose for the second-stage dose expansion study. This dose expansion study aims to determine the schedule for a Phase 2 trial in patients with relapsed/refractory AML and to also provide an early efficacy assessment of AB8939.

03

Conditions studied

  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • Myelodysplastic Syndrome Acute Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DOSE ESCALATION STUDY

Key Inclusion Criteria:

  • Patients with documented diagnosis of acute myeloid leukemia (AML) based on the last version of the World Health Organization classification and eligible to second or of treatment.
  • Patients with documented diagnosis of melyodisplastic syndrome in second or third line of treatment, and with high risk at prognosis based on the IPSS-R scoring system.
  • performance status ≤ 1
  • Patients are able to understand, sign, and date the written form at screening visit prior to any protocol-specific procedures
  • Patients are able and willing to comply with study procedures as per protocol, including bone marrow

Key Exclusion Criteria:

  • Patients eligible to a standard of care
  • Patients eligible to hematopoietic stem cell transplantation () at the time of inclusion
  • Patients diagnosed with acute promyelocytic leukemia (M3)
  • Patients with clinically active CNS leukemia
  • Patients with HSCT within 100 days prior to the first administration of AB8939
  • Women who are lactating/breastfeeding or who plan to breastfeed while on study
  • Women with a positive pregnancy test

Other protocol-defined inclusion/exclusion criteria may apply

EXPANSION COHORT STUDY

Key Inclusion Criteria:

  • Patients with documented diagnosis of acute myeloid leukemia (AML) based on the last version of the World Health Organization classification and eligible to second or third line of treatment.
  • ECOG performance status ≤ 2
  • Patients are able to understand, sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures
  • Patients are able and willing to comply with study procedures as per protocol, including bone marrow biopsies

Key Exclusion Criteria:

  • Patients eligible to a standard of care
  • Patients eligible to hematopoietic stem cell transplantation (HSCT) at the time of inclusion
  • Patients diagnosed with acute promyelocytic leukemia (M3)
  • Patients with clinically active CNS leukemia
  • Patients with HSCT within 100 days prior to the first administration of AB8939
  • Women who are lactating/breastfeeding or who plan to breastfeed while on study
  • Women with a positive pregnancy test

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    AB8939

    AB8939 administered as a single agent

    Drug: AB8939

  • Experimental
    AB8939 plus Venetoclax

    AB8939 administered in combination with venetoclax

    Drug: AB8939 · Drug: Venetoclax

Interventions

  • DrugAB8939

    Intravenous injection (from an initial dose of 0.9 mg/m²)

  • the recommended starting dose for AML indication is 100 mg. Dose escalating regimen as per SmPC.

06

What researchers measure

Primary outcomes

  1. Rate of dose limiting toxicity (DLT)

    Identification of the Maximal Tolerated Dose for different dosing schedules

    Time frame: Up to 56 days

Secondary outcomes

  1. Objective Response Rate

    The proportion of patients who have a partial or complete response to therapy

    Time frame: Up to 56 days

07

Study locations

8 of 10 sites recruiting
08

References and documents

Publications

  • Goubard A, Humbert M, Mansfield C, Hermine O, Dubreuil P, et al. In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-derived Xenograft Models of Acute Myeloid Leukemia. Blood (2019) 134 (Supplement_1): 5142. doi.org/10.1182/blood-2019-127143
  • Goubard A, Humbert M, Mansfield C, Hermine O, Dubreuil P, et al. AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, is Active Across the Range (M0-M7) of Acute Myeloid Leukemia Subtypes. Blood (2019) 134 (Supplement_1): 5154. doi.org/10.1182/blood-2019-127021
  • Humbert M, Goubard A, Mansfield C, Hermine O, Dubreuil P, et al. Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939. Blood (2019) 134 (Supplement_1): 2075. doi.org/10.1182/blood-2019-122540
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Aug 2026, 50 months after the start.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 50 months is below that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2022
First posted
Jan 27, 2022
StartActual
Jun 1, 2022
Primary completionEst.
Aug 2026
CompletionEst.
Dec 2026
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05211570
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Jun 1, 2022
Primary completion
Aug 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 2, 2025

Study contacts

Clinical Study Coordinator
Contact
clinical@ab-science.com
+33(0)147200014
Norbert Vey, MD
principal investigator · Institut Paoli Calmettes, Marseille, France
Nicholas Short, MD
principal investigator · MD Anderson Cancer Center, Houston, Texas

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion